A systematic pan-cancer analysis shows that oncogene CDK1 is an immunological and prognostic biomarker, which may influence tumor immunity mainly by mediating the migration of immune cells to TME, and is positively associated with tumor mutational burden and microsatellite instability (54). The gene discussed is CDK1; the disease is cancer.